AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02284607
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to MHAA4549A administration
Trial: NCT01314066
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients assigned to placebo-control group will receive a single dose of saline solution as a 90 minute IV infusion
Trial: NCT00281632
Drug: GW786034
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg GW786034 administered orally on a daily basis.
Trial: NCT01542437
Drug: BIBW 2992
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive: BIBW 2992 40mg every 24 hours orally, where a cycle corresponds to complete this treatment for 28 days; option 30mg/day dose reductions, according to established criteria.~Not to be compared with any other drug.
Trial: NCT04012905
Drug: Corticosteroids for Systemic Use
RxNorm normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids tapering over 28 weeks:~J0 = 0,7 mg/kg S2 = 0,6 mg/kg S4 = 0,5 mg/kg S6 = 0,4 mg/kg S8 = 0,3 mg/kg S10 = 0,25 mg/kg S12 = 0,2 mg/kg S14 = 0,15 mg/kg S16 = 0,15 mg/kg S20 = 0,1 mg/kg S24 = 0,05 mg/kg S28 = 0 mg/kg~Corticosteroids tapering over 52 weeks:~J0 = 0,7 mg/kg S2 = 0,6 mg/kg S4 = 0,6 mg/kg S6 = 0,5 mg/kg S8 = 0,4 mg/kg S10 = 0,3 mg/kg S12 = 0,25 mg/kg S14 = 0,2 mg/kg S16 = 0,175 mg/kg S20 = 0,15 mg/kg S24 = 0,125 mg/kg S28 = 0,01 mg/kg S32 to S52: - 1mg per month
Trial: NCT04064242
Drug: CMK389
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single i.v. dose every 4 weeks
Trial: NCT04064242
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single i.v. dose every 4 weeks
Trial: NCT00827515
Drug: PH797804
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 5mg PH797804 as an immediate release tablet formulation in the fasted state
Trial: NCT00827515
Drug: PH797804
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 5mg PH797804 as an immediate release tablet formulation in the fed state
Trial: NCT04577326
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A preconditioning regimen of one dose of intravenous (IV) cyclophosphamide 1.5 g/m\^2 will be administered 2-7 days before the infusion.
Trial: NCT01491815
Drug: Non-biological DMARD's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate: 25mg/week. SSZ: 2 g/day. HCQ: 35 mg/kg/week (Finland and Denmark) Methotrexate: 25mg/week. Prednisolone 20 mg/day tapered in 9 weeks to 5 mg/day, discontinued after 9 months. (Sweden, Norway, Iceland, and the Netherlands)
Trial: NCT03144271
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of placebo will be administered subcutaneously (s.c. under the skin)
Trial: NCT03644485
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will receive induction therapy. The dosage and administration of induction immunotherapy will be a single kind of drug determined by the investigator.
Trial: NCT03644485
Drug: Mycophenolic acid drugs
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants will receive mycophenolic acid drugs in combination with corticosteroids. The dosage and administration of mycophenolic acid will be determined by the investigator.
Trial: NCT05488990
Drug: AKVANO vehicle formulation 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel lipid based formulation (AKVANO) vehicle 1
Trial: NCT03644485
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will receive corticosteroids in combination with mycophenolic acid drugs. The dosage and administration of corticosteroids will be determined by the investigator.
Trial: NCT01321554
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo (two 10-mg and one 4-mg lenvatinib matched capsules) taken orally once daily, continuously.
Trial: NCT05488990
Drug: AKVANO vehicle formulation 2
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel lipid based formulation (AKVANO) vehicle 2
Trial: NCT00048932
Drug: Double-blind Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrate and diluted in a solution, IV, 0 mg, Once daily, Day 1, 15, and 29.
Trial: NCT00502684
Drug: Propranolol, etodolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propranolol 10 mg X 4 /day, starting on day -3 pre-op, for 6 days, till POD 2 Etodolac 400 mg X2/day, starting on day -3 pre-op, for 6 days, till POD 2
Trial: NCT01487460
Drug: TAP311
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01986881
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to ertugliflozin administered orally, once daily, for up to approximately 6 years
Trial: NCT00672581
Drug: ZD4054
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg, Oral tablet, single dose
Trial: NCT01323595
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 200mg PO BID x 6 days
Trial: NCT02222480
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00791661
Drug: MK-1006
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-1006 capsules in single oral doses beginning at 15 mg and rising to 45 mg in Panel A, beginning at 60 mg and rising to 80 mg and 60 mg fed state in Panel B, or beginning at 100 mg and rising to 170 mg in Panel C.
Trial: NCT00791661
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to MK-1006 in a single oral dose
Trial: NCT04229602
Drug: EFEXOR® XR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EFEXOR® XR (75mg) produced by Pfizer Ireland Pharmaceuticals(held by Pfizer Healthcare Ireland, distributed by Wyeth pharmaceutical co. LTD)
Trial: NCT03614078
Drug: PRCL-02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT03614078
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT01308606
Drug: TMC435 HPMC capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intake of one 150-mg capsule without food
Trial: NCT00002801
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04083716
Drug: ABI-H2158 Reference Formulation
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABI-H2158 tablets Reference Formulation
Trial: NCT04083716
Drug: ABI-H2158 Test Formulation
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABI-H2158 tablets Test Formulation
Trial: NCT00135018
Drug: celecoxib and chemotherapy
RxNorm normalized name: amlodipine and celecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03830320
Drug: [64Cu]FBP8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of Copper-64 radiopeptide to detect thrombosis
Trial: NCT02338999
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01603108
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin placebo will be initiated post LT, once the subject is able to tolerate oral medications/diet. Rifaximin placebo dosed at 550 mg twice daily for 90 days (+/10 days) post LT.
Trial: NCT02860949
Drug: 0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg mixed NSS up to 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02004886
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets matching MK-0893
Trial: NCT02004886
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets matching metformin
Trial: NCT02247596
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill 1g tds for 2 weeks
Trial: NCT04190628
Drug: ABM-1310
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A: Starting dose at 25 mg by mouth twice daily.~Part B: Starting dose at a dose below the MTD( Maximum Tolerated Dose) that has been demonstrated to be safe in Part A.~Part C-1 and C-2: Continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part A until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.~Part C-3 and C-4: Continuous twice daily oral doses of ABM-1310 at the recommended phase 2 dose (RP2D) from Part B until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion is met.
Trial: NCT02318043
Drug: inhaled corticosteroids (usually budesonide/fomorterol 160/4.5mcg; fluticasone/salmeterol 250/50mcg)
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with uncontrolled and partly controlled asthma, following accomplishment of study 1, were invited to participate in observational study (study 2), which sought to determine usefulness of both BPTs in reflecting improvement of asthmatic symptoms following 3 and 6 months of moderate-dose ICSs treatment (400\~800μg budesonide or equivalent). Patient continued to administer their original ICS during follow-up. During two follow-up visits (3 months apart), AMP-BPT, His-BPT and Hogg's symptom scores were reassessed.
Trial: NCT02638506
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients will receive a 1.5 mcg⁄kg dose of fentanyl. This will be administered intranasally via a mucosal atomiser device (MAD) using 50 mcg/mL solution with a 2 mL syringe
Trial: NCT03737110
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo SC injections once weekly
Trial: NCT03312153
Drug: Neem
RxNorm normalized name: neem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A natural irrigant solution act as anti-inflammatory and anti bacterial
Trial: NCT00662857
Drug: Technosphere® Insulin Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TI Inhalation Powder, two 15 U cartridges
Trial: NCT00662857
Drug: Technosphere Insulin® Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TI Inhalation Powder, one 30 U cartridge
Trial: NCT01558310
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized into one of two groups. Group A will receive ustekinumab at week 0, 4, 16, 28, and week 40 and placebo at week 12 and 52. The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses
Trial: NCT01010425
Drug: ACP-001 (TransCon PEG hGH)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACP-001, dose-level 1, s.c., single-dose
Trial: NCT01010425
Drug: ACP-001 (TransCon PEG hGH)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACP-001, dose-level 2, s.c., single-dose
Trial: NCT01010425
Drug: ACP-001 (TransCon PEG hGH)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACP-001, dose-level 3, s.c., single-dose
Trial: NCT01010425
Drug: ACP-001 (TransCon PEG hGH)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACP-001, dose-level 4, s.c., single-dose
Trial: NCT01010425
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, s.c., single-dose
Trial: NCT02275780
Drug: TRUVADA™ or EPZICOM™/KIVEXA™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigator selects either TRUVADA™, a tablet containing 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate p.o. q.d. or EPZICOM™/KIVEXA™, a tablet containing 600 mg abacavir sulfate and 300 mg lamivudine, p.o. q.d.
Trial: NCT00679289
Drug: HDI
RxNorm normalized name: Fanhdi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 MU/m\^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m\^2 SC 3 days/week until disease progression
Trial: NCT03460457
Drug: TQB2450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacokinetics/Dynamics Study
Trial: NCT00994851
Drug: SENNA+CASSIA
RxNorm normalized name: Padang cassia oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: capsule Route of administration: oral Dose regimen: once a day
Trial: NCT00994851
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Capsule Route of administration: oral Dose regimen: once a day
Trial: NCT04143594
Drug: TAF
RxNorm normalized name: Altafed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered without regard to food
Trial: NCT04143594
Drug: B/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered without regard to food
Trial: NCT01208506
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of NNC0114-0000-0005 placebo.
Trial: NCT03706885
Drug: Sustiva Pill
RxNorm normalized name: Sustiva Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One pill (Sustiva 50 mg or Sustiva 200mg or Placebo) One pill per day for 20 weeks
Trial: NCT00093587
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00154232
Drug: Enteric-Coated Mycophenolate Sodium (EC-MPS)
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02323646
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
Trial: NCT01154348
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet, taken once daily with morning meal
Trial: NCT00687570
Drug: Laxabon®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laxabon® 4 litres starting the day before surgery
Trial: NCT00703092
Drug: Fiber-Stat
RxNorm normalized name: Fiber-Stat with FOS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid fiber supplement, 2 tablespoons twice daily.
Trial: NCT04325425
Drug: FOLFOXIRI Protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-Etoposide regimen will be administered once every 21 days. Treatment will be continued for 6 to 8 cycles or 24 weeks maximum. One cycle consists of 21 days (3 weeks) with injection on D1 of each cycle (D1=D22). Patients are eligible for repeated treatment cycles in the absence of disease progression and undue adverse events.
Trial: NCT02255305
Drug: Antimicrobials
RxNorm normalized name: ANTIMICROBIALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to the control group will receive antimicrobials targeting C. difficile.
Trial: NCT01544998
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The pharmacy will create a placebo subcutaneous injection volume to match the volume of Nesiritide dose.
Trial: NCT03107078
Drug: Glucocorticoids
RxNorm normalized name: GLUCOCORTICOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Glucocorticoids (GCs)
Trial: NCT02231138
Drug: Abelmoschus manihot (AM)
RxNorm normalized name: Abelmoschus manihot whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abelmoschus manihot (AM): Huanghui capsule (Jiangsu Suzhong Pharmaceutical Group Co., Ltd.), 0.5 g × 30 capsules/box. A huangkui capsule is a single plant drug extract of Flos Abelmoschus manihot.
Trial: NCT00514683
Drug: intermediate dose BIBF 1120 twice daily
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intermediate dose BIBF 1120 twice daily
Trial: NCT00514683
Drug: high dose BIBF 1120 twice daily
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: high dose BIBF 1120 twice daily
Trial: NCT00514683
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT04546399
Drug: Hydrocortisone Sodium Succinate
RxNorm normalized name: Hydrocortisone Sodium Succinate
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IT
Trial: NCT04546399
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04546399
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT, PO, and IV
Trial: NCT02417103
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04684628
Drug: 68Ga-PSMA PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of 68Ga-PSMA-11 followed by a PET/CT scan at 45 min after injection.
Trial: NCT03395184
Drug: PF-06651600 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 weeks, followed by PF-06651600, 50 mg once daily (QD) for 52 weeks
Trial: NCT00810836
Drug: BG00012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00810836
Drug: BG00012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT03207464
Drug: [C-11]Methylreboxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 individuals with Multiple Sclerosis and 4 healthy controls will undergo a \[C-11\]MRB PET scan and a MRI scan.
Trial: NCT00810836
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral placebo
Trial: NCT00790452
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet daily by mouth
Trial: NCT04296916
Drug: IOP lowering eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Latanoprost 0.005% eye drops will be the first choice. If an IOP reduction of 20% is not achieved within three months, timolol 0.5% will be added as second medication. If an IOP reduction of 20% is then not achieved, alphagan 0.2% or alphagan-P 0.15% will be added. If an IOP reduction of 20% is then not achieved, the individual will be excluded from the study.~2. If necessary, latanoprost will be switched to other prostaglandin eye drops, alphagan (or alphagan-P) will be switched to brinzolamide 1% eye drops.~3. If necessary, latanoprost and timolol will be switched to Xalacom eye drops, timolol and alphagan will be switched to Combigan eye drops, timolol and brinzolamide will be switched to Azarga eye drops.~4. Once daily in the evening for prostaglandin eye drops, and twice daily for other eye drops.
Trial: NCT01290978
Drug: DuraPrep
RxNorm normalized name: DuraPrep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The application sites (subjects' backs) will be prepped with DuraPrep according to manufacturer's instruction. Samples of 3 surgical incise drapes will be applied to the prepped sites according to randomization schedule
Trial: NCT01095978
Drug: Clarithromycin (Klacid SR)
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Klacid SR in a dose of 1000 mg once daily
Trial: NCT03088709
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV medication given for prevention of graft versus host disease.
Trial: NCT00650195
Drug: Zaroloxyn® Tablets 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg, single dose fasting
Trial: NCT01904864
Drug: elemental iron (NovaFerrum®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, NovaFerrum®, for 12 weeks
Trial: NCT01904864
Drug: elemental iron (Ferrous Sulfate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, Ferrous Sulfate, for 12 weeks
Trial: NCT01260883
Drug: Ketorolac Tromethamine 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac Tromethamine 1 mg/kg infusion over 10 minutes intravenous (IV) infusion. Blood sampling in for up to 12 hours after infusion for analysis of ketorolac concentrations and safety assessments.
Trial: NCT03793725
Drug: SHR1210
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-1 Antibody
Trial: NCT00191282
Drug: Human insulin isophane suspension (NPH)
RxNorm normalized name: insulin isophane, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values \>8.0%
Trial: NCT00191282
Drug: Human insulin isophane suspension
RxNorm normalized name: insulin isophane, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient adjusted dose, twice daily, injected subcutaneous (SC) before morning and evening meals until patient completes study.
Trial: NCT00191282
Drug: Human insulin 30/70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values \>8.0%.
Trial: NCT03152955
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sufentanil(0.02ug/kg/h) is applied in patient-controlled analgesia.